

測試報告

報告編號： PUG22400882

日期： 2022年05月09日

頁數： 1 of 9



生麗國際股份有限公司
桃園市桃園區中正路1353號15樓

以下測試之樣品係由申請廠商所提供及確認：

產品名稱： 6C 完美輕透防曬霜 PERFECT ULTRA-LIGHT SUNSCREEN
申請廠商： 生麗國際股份有限公司
申請廠商地址： 桃園市桃園區中正路1353號15樓
電話/聯絡人： 03-2151011 / 生麗國際股份有限公司
樣品包裝： 請參考報告末頁樣品照片
數量： 4 pcs
樣品保存方式： 室溫
產品型號： ---
產品批號： 2021.03.10A
製造/國內負責廠商： 生麗國際股份有限公司
製造日期： 2021.03.10
有效期限： 2024.03.09
收樣日期： 2022年04月21日
測試日期： 2022年04月21日 ~ 2022年05月09日

測試結果： -請見下頁-

陳新智

陳新智 經理
台灣檢驗科技股份有限公司
報告簽署人



This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號： PUG22400882

日期： 2022年05月09日

頁數： 2 of 9



生麗國際股份有限公司
桃園市桃園區中正路1353號15樓

測試結果：

| 測試項目 | CAS NO. | 測試方法 | 測試結果 | 定量/偵測極限 | 單位 |
|--------------------------|---------|------------------------------------------------------------------------------------------------------------|------|---------|-----------|
| 365項西藥定性分析 | --- | --- | --- | --- | --- |
| 本樣品檢測共365項西藥定性分析(項目詳見附錄) | | 本測試依實驗室內部方法(TESP-UB-0173, TESP-UB-0181, TESP-UB-0182), 以薄層層析法(TLC), 液相層析離子阱質譜儀(LC/MS/MS)或氣相層析質譜儀(GC/MS)檢測。 | N.D. | --- | ppm(µg/g) |

備註：

1. 測試報告僅就委託者之委託事項提供測試結果，不對產品合法性做判斷。
2. 本測試報告之所有檢驗內容，均依委託事項執行檢驗，如有不實，願意承擔完全責任。
3. 本報告不得分離，分離使用無效。
4. 若該測試項目屬於定量分析則以「定量極限」表示；若該測試項目屬於定性分析則以「偵測極限」表示。
5. 低於定量極限/偵測極限之測定值以「N.D.」或「陰性」表示。微生物測試低於定量極限以「<定量極限值」表示。

- END -

報告編號： PUG22400882

日期： 2022年05月09日

頁數： 3 of 9



生麗國際股份有限公司
桃園市桃園區中正路1353號15樓

附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm(μ g/g)

| 測試項目 | CAS NO. | LOD | 測試項目 | CAS NO. | LOD |
|-------------------------------|--------------|------|----------------------------|-------------|------|
| 2,4-Dinitrophenol | 51-28-5 | 3600 | Benzathine-penicillin | 41372-02-5 | 3300 |
| 2-Diphenylmethylpyrrolidine | 22348-31-8 | 900 | Benzbromarone | 3562-84-3 | 900 |
| 7-keto-Dehydroepiandrosterone | 566-19-8 | 3000 | Benzhexol | 144-11-6 | 1800 |
| Acetaminophen | 103-90-2 | 300 | Benzocaine | 94-09-7 | 300 |
| Acetil acid | 147676-78-6 | 1500 | Benzylamine | 642-72-8 | 348 |
| Acetildenafil | 831217-01-7 | 600 | Betamethasone | 378-44-9 | 900 |
| Acetohexamide | 968-81-0 | 750 | Betamethasone 21 Acetate | 987-24-6 | 4500 |
| Acetophenetidin | 62-44-2 | 3600 | Betamethasone Benzoate | 22298-29-9 | 3225 |
| Acetylvardenafil | 1261351-28-3 | 600 | Betamethasone Dipropionate | 5593-20-4 | 1050 |
| Acrinol | 1837-57-6 | 2832 | Betamethasone Valerate | 2152-44-5 | 108 |
| Allopurinol | 315-30-0 | 600 | Bezafibrate | 41859-67-0 | 600 |
| Ambroxol | 18683-91-5 | 600 | Bisacodyl | 603-50-9 | 600 |
| Aminophylline | 317-34-0 | 4500 | Bisoprolol Fumarate | 104344-23-2 | 60 |
| Aminopyrine | 58-15-1 | 900 | Bromhexine | 3572-43-8 | 1200 |
| Aminotadalafil | 385769-84-6 | 900 | Bromopride | 4093-35-0 | 60 |
| Amitriptyline | 549-18-8 | 750 | Brompheniramine | 86-22-6 | 1800 |
| Amlodipine | 88150-42-9 | 300 | Bromvalerylurea | 496-67-3 | 1950 |
| Amoxicillin | 26787-78-0 | 4320 | Bucetin | 1083-57-4 | 600 |
| Amphetamine | 300-62-9 | 375 | Bufexamac | 2438-72-4 | 1650 |
| Ampicillin | 69-53-4 | 2700 | Buspirone | 36505-84-7 | 3600 |
| Apomorphine | 58-00-4 | 600 | Butropium | 107080-63-7 | 3000 |
| Aspirin | 50-78-2 | 600 | Caffeine | 58-08-2 | 600 |
| Astemizole | 68844-77-9 | 150 | Camyllofine | 54-30-8 | 3000 |
| Atenolol | 29122-68-7 | 300 | Carbamazepine | 298-46-4 | 3600 |
| Atorvastatin | 134523-00-5 | 420 | Carbetapentane | 77-23-6 | 150 |
| Atropine | 51-55-8 | 150 | Carbimazole | 22232-54-8 | 600 |
| Avanafil | 330784-47-9 | 600 | Carbinoxamine | 486-16-8 | 1650 |
| Baclofen | 1134-47-0 | 300 | Carbodenafil | 944241-52-5 | 1500 |
| Barbital | 57-44-3 | 750 | Carisoprodol | 78-44-4 | 375 |
| Benazepril | 86541-75-5 | 450 | Carvedilol | 72956-09-3 | 2400 |
| Benproperine | 2156-27-6 | 600 | Cefamandole nafate | 42540-40-9 | 150 |

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號： PUG22400882

日期： 2022年05月09日

頁數： 4 of 9



生麗國際股份有限公司
桃園市桃園區中正路1353號15樓

附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm(μ g/g)

| 測試項目 | CAS NO. | LOD | 測試項目 | CAS NO. | LOD |
|------------------------|-------------|------|-------------------------|-------------|------|
| Cefazolin | 25953-19-9 | 1050 | Cloperastine | 3703-76-2 | 1500 |
| Cefoperazone dihydrate | 113826-44-1 | 300 | Clotrimazole | 23593-75-1 | 3000 |
| Cefotaxime | 63527-52-6 | 150 | Cloxacillin Sodium | 7081-44-9 | 4770 |
| Ceftriaxone | 73384-59-5 | 4224 | Clozapine | 5786-21-0 | 600 |
| Celecoxib | 169590-42-5 | 900 | Cocaine | 50-36-2 | 750 |
| Cephalexin | 15686-71-2 | 75 | Colchicine | 64-86-8 | 750 |
| Cephradine | 38821-53-3 | 81 | Cortisone | 53-06-5 | 750 |
| Cetilistat | 282526-98-1 | 1500 | Cortisone acetate | 50-04-4 | 3600 |
| Cetirizine | 83881-51-0 | 159 | Cyproheptadine | 129-03-3 | 1500 |
| Chloramphenicol | 56-75-7 | 1200 | Desacetyl bisacodyl | 603-41-8 | 600 |
| Chlordiazepoxide | 58-25-3 | 300 | Desacetyl diltiazem | 42399-40-6 | 60 |
| Chlorhexidine | 55-56-1 | 2400 | Dexamethasone | 50-02-2 | 1200 |
| Chlormezanone | 80-77-3 | 60 | Dexamethasone phosphate | 312-93-6 | 900 |
| Chloropretadalafil | 171489-59-1 | 1500 | Dextromethorphan | 125-71-3 | 1500 |
| Chlorothiazide | 58-94-6 | 750 | Diazepam | 439-14-5 | 300 |
| Chlorpheniramine | 113-92-8 | 1200 | Dibucaine | 85-79-0 | 450 |
| Chlorpromazine | 50-53-3 | 300 | Diclofenac | 15307-86-5 | 600 |
| Chlorpropamide | 94-20-2 | 600 | Dicyclomine | 77-19-0 | 375 |
| Chlortetracycline | 57-62-5 | 600 | Diethylpropion | 39648-50-5 | 450 |
| Chlorzoxazone | 95-25-0 | 1050 | Diethylstilbestrol | 56-53-1 | 600 |
| Cimetidine | 51481-61-9 | 1500 | Difloxacin | 98106-17-3 | 3000 |
| Cinnarizine | 298-57-7 | 600 | Digitoxin | 71-63-6 | 450 |
| Ciprofloxacin(CFA) | 85721-33-1 | 240 | Dihydroergotamine | 511-12-6 | 150 |
| Clenbuterol | 21898-19-1 | 900 | Diltiazem | 42399-41-7 | 300 |
| Clindamycin HCl | 21462-39-5 | 456 | Dimenhydrinate | 523-87-5 | 150 |
| Clindamycin phosphate | 24729-96-2 | 150 | Dimethylsildenafil | 496835-35-9 | 3000 |
| Clobenzorex | 13364-32-4 | 375 | Dimetridazole | 551-92-8 | 150 |
| Clobetasol Propionate | 25122-46-7 | 2400 | Diphenhydramine | 58-73-1 | 375 |
| Clofibrate | 637-07-0 | 1500 | Diphenylhydantoin | 57-41-0 | 150 |
| Clonazepam | 1622-61-3 | 150 | Diprophylline | 479-18-5 | 900 |
| Clonidine | 4205-90-7 | 300 | Dipyridamole | 58-32-2 | 450 |

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號： PUG22400882

日期： 2022年05月09日

頁數： 5 of 9



生麗國際股份有限公司
桃園市桃園區中正路1353號15樓

附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm(μ g/g)

| 測試項目 | CAS NO. | LOD | 測試項目 | CAS NO. | LOD |
|-------------------------------|--------------|------|---------------------------|-------------|-------|
| Dipyron | 68-89-3 | 600 | Fluocinonide | 356-12-7 | 3600 |
| Dithio-desmethyl-carbodenafil | 1333233-46-7 | 1500 | Fluoxetine | 54910-89-3 | 1200 |
| Doxazosin | 74191-85-8 | 2400 | Fluoxymesterone | 76-43-7 | 600 |
| Doxycycline | 564-25-0 | 576 | Flurbiprofen | 5104-49-4 | 150 |
| Doxylamine | 469-21-6 | 60 | Fluvastatin | 93957-54-1 | 1200 |
| Dyclonine Hydrochloride | 536-43-6 | 3600 | Furosemide | 54-31-9 | 600 |
| Econazole | 27220-47-9 | 150 | Gemfibrozil | 25812-30-0 | 4500 |
| Enrofloxacin | 93106-60-6 | 3090 | Gendenafil | 147676-66-2 | 3000 |
| Eprazinone | 10402-90-1 | 300 | Glibenclamide | 10238-21-8 | 4800 |
| Erythromycin | 114-07-8 | 240 | Glimepiride | 93479-97-1 | 2400 |
| Estazolam | 29975-16-4 | 60 | Glipizide | 29094-61-9 | 3000 |
| Estradiol | 50-28-2 | 1200 | Glycopyrronium | 740028-90-4 | 900 |
| Estradiol benzoate | 50-50-0 | 600 | Griseofulvin | 126-07-8 | 450 |
| Estriol | 50-27-1 | 60 | Guaifenesin | 93-14-1 | 2400 |
| Estrone | 53-16-7 | 30 | Haloperidol | 52-86-8 | 1620 |
| Ethinyl estradiol | 57-63-6 | 30 | Homatropine | 87-00-3 | 150 |
| Ethisterone | 434-03-7 | 600 | Homosildenafil | 642928-07-2 | 1350 |
| Ethoxybenzamide | 938-73-8 | 600 | Hydralazine | 86-54-4 | 450 |
| Ethylestrenol | 965-90-2 | 30 | Hydrochlorothiazide | 58-93-5 | 600 |
| Etodolac | 41340-25-4 | 600 | Hydrocortisone | 50-23-7 | 750 |
| Etofibrate | 31637-97-5 | 3000 | Hydroxyacetildenafil | 147676-56-0 | 600 |
| Famotidine | 76824-35-6 | 750 | Hydroxyhomosildenafil | 139755-85-4 | 1200 |
| Fenbufen | 36330-85-5 | 1875 | Hydroxythiohomosildenafil | 479073-82-0 | 1650 |
| Fenfluramine | 458-24-2 | 375 | Hydroxyvaridenafil | 224785-98-2 | 1500 |
| Fenofibrate | 49562-28-9 | 150 | Hydroxyzine | 2192-20-3 | 900 |
| Fenoterol | 13392-18-2 | 750 | Ibuprofen | 15687-27-1 | 1200 |
| Finasteride (Proscar) | 98319-26-7 | 3000 | Imidazosagatriazinone | 139756-21-1 | 1200 |
| Flavoxate | 15301-69-6 | 900 | Imipramine | 50-49-7 | 60 |
| Flibanserin | 167933-07-5 | 3600 | Indapamide | 26807-65-8 | 2400 |
| Fluconazole | 86386-73-4 | 480 | Indomethacin | 53-86-1 | 1200 |
| Flufenamic acid | 530-78-9 | 4050 | Isoniazid | 54-85-3 | 302.4 |

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號： PUG22400882

日期： 2022年05月09日

頁數： 6 of 9



生麗國際股份有限公司
桃園市桃園區中正路1353號15樓

附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm(μ g/g)

| 測試項目 | CAS NO. | LOD | 測試項目 | CAS NO. | LOD |
|---------------------------|-------------|------|---------------------------|-------------|------|
| Ketoconazole | 65277-42-1 | 300 | Metronidazole | 443-48-1 | 900 |
| Ketoprofen | 22071-15-4 | 450 | Mexiletine | 31828-71-4 | 1500 |
| Ketotifen fumarate | 34580-14-8 | 60 | Midazolam | 59467-70-8 | 60 |
| Lidocaine | 137-58-6 | 60 | Minocycline | 10118-90-8 | 750 |
| Lincomycin | 154-21-2 | 1710 | Minoxidil | 38304-91-5 | 600 |
| Liothyronine | 6893-02-3 | 3600 | Morphine | 57-27-2 | 150 |
| Lomefloxacin | 98079-51-7 | 1500 | Nalidixic acid | 389-08-2 | 300 |
| Lorazepam | 846-49-1 | 300 | Naloxone | 465-65-6 | 384 |
| Lorcaserin | 616202-92-7 | 900 | Naltrexone | 16590-41-3 | 2370 |
| Maprotiline | 10262-69-8 | 150 | Nandrolone | 434-22-0 | 750 |
| Mazindol | 22232-71-9 | 1950 | Naphazoline Hydrochloride | 835-31-4 | 300 |
| Meclizine | 569-65-3 | 60 | Naproxen | 22204-53-1 | 900 |
| Mefenamic acid | 61-68-7 | 900 | N-Desethylvardenafil | 448184-46-1 | 3000 |
| Melatonin | 73-31-4 | 1200 | N-Desmethylacetildenafil | 147676-55-9 | 3000 |
| Meloxicam | 71125-38-7 | 4500 | N-Desmethylsibutramine | 168835-59-4 | 3000 |
| Meperidine | 57-42-1 | 150 | N-Desmethylsildenafil | 139755-82-1 | 3000 |
| Mephenesin | 59-47-2 | 150 | N-Didesmethylsibutramine | 84467-54-9 | 3000 |
| Mephentermine | 100-92-5 | 240 | Nefopam | 13669-70-0 | 300 |
| Meprobamate | 57-53-4 | 375 | Nicametate | 3099-52-3 | 2550 |
| Metformin | 657-24-9 | 300 | Nicotine | 54-11-5 | 60 |
| Methamphetamine | 537-46-2 | 750 | Nifedipine | 21829-25-4 | 600 |
| Methandriol | 521-10-8 | 2400 | Nifuroxazide | 965-52-6 | 540 |
| Methandrostenolone | 72-63-9 | 600 | Nitrazepam | 146-22-5 | 600 |
| Methaqualone | 72-44-6 | 900 | Nitrofurantoin | 67-20-9 | 450 |
| Metharbital | 50-11-3 | 750 | Nitrofurazone | 59-87-0 | 4410 |
| Methimazole | 60-56-0 | 300 | Noracetildenafil | 949091-38-7 | 300 |
| Methyl DOPA-Sesquihydrate | 41372-08-1 | 1620 | Noraminyprine | 519-98-2 | 2400 |
| Methylprednisolone | 83-43-2 | 750 | Norethisterone | 68-22-4 | 600 |
| Methyltestosterone | 58-18-4 | 600 | Norfloxacin | 70458-96-7 | 300 |
| Metoclopramide | 364-62-5 | 750 | Norfludiazepam | 2886-65-9 | 150 |
| Metoprolol | 51384-51-1 | 150 | Norgestrel | 6533-00-2 | 600 |

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號： PUG22400882

日期： 2022年05月09日

頁數： 7 of 9



生麗國際股份有限公司
桃園市桃園區中正路1353號15樓

附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm(μ g/g)

| 測試項目 | CAS NO. | LOD | 測試項目 | CAS NO. | LOD |
|-----------------------|-------------|------|----------------|-------------|------|
| Norneosildenafil | 371959-09-0 | 1000 | Piperidenafil | 224788-34-5 | 1500 |
| Nortadalafil | 171596-36-4 | 1500 | Pirenzepine | 28797-61-7 | 1350 |
| Noscapine | 128-62-1 | 300 | Piroxicam | 36322-90-4 | 600 |
| Nylidrin | 849-55-8 | 4500 | Prazosin | 19216-56-9 | 300 |
| Ofloxacin | 82419-36-1 | 1920 | Prednisolone | 50-24-8 | 1200 |
| Omeprazole | 73590-58-6 | 1200 | Prednisone | 53-03-2 | 750 |
| Orlistat | 96829-58-2 | 375 | Prilocaine | 721-50-6 | 750 |
| Orphenadrine | 83-98-7 | 300 | Primidone | 125-33-7 | 30 |
| Oxeladin | 468-61-1 | 120 | Probenecid | 57-66-9 | 900 |
| Oxethazaine | 126-27-2 | 150 | Procaine | 59-46-1 | 300 |
| Oxybutynin | 5633-20-5 | 4635 | Progesterone | 57-83-0 | 600 |
| Oxymetholone | 434-07-1 | 1050 | Promethazine | 60-87-7 | 300 |
| Oxyphenbutazone | 129-20-4 | 450 | Propafenone | 54063-53-5 | 2400 |
| Oxyphencyclimine | 125-53-1 | 75 | Propantheline | 298-50-0 | 3000 |
| Oxytetracycline (OTC) | 79-57-2 | 960 | Propranolol | 525-66-6 | 1350 |
| Papaverine | 58-74-2 | 1560 | Propyphenazone | 479-92-5 | 3000 |
| Pentazocine | 359-83-1 | 30 | Quetiapine | 111974-69-7 | 2400 |
| Pentobarbital | 76-74-4 | 150 | Quinine | 130-95-0 | 300 |
| Pentoxifylline | 6493-05-6 | 2400 | Ranitidine | 66357-59-3 | 600 |
| Phenacetin | 62-44-2 | 3600 | Reserpine | 50-55-5 | 1200 |
| Phenazopyridine | 94-78-0 | 750 | Rifampin | 13292-46-1 | 120 |
| Phenformin | 114-86-3 | 900 | Rimonabant | 168273-06-1 | 3000 |
| Phenobarbital | 50-06-6 | 900 | Rosiglitazone | 122320-73-4 | 3000 |
| Phenolphthalein | 77-09-8 | 600 | Salbutamol | 18559-94-9 | 37.5 |
| Phentermine | 122-09-8 | 1500 | Salicylamide | 65-45-2 | 600 |
| Phentolamine | 50-60-2 | 1500 | Salicylic acid | 69-72-7 | 900 |
| Phenylbutazone | 50-33-9 | 750 | Santonin | 481-06-1 | 450 |
| Phenylephrine | 59-42-7 | 2850 | Scopolamine | 6533-68-2 | 150 |
| Phenylpropanolamine | 14838-15-4 | 60 | Secobarbital | 76-73-3 | 900 |
| Pioglitazone | 111025-46-8 | 1200 | Sibutramine | 106650-56-0 | 1200 |
| Piperiacetildenafil | 147676-50-4 | 3000 | Sildenafil | 139755-83-2 | 1200 |

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號： PUG22400882

日期： 2022年05月09日

頁數： 8 of 9



生麗國際股份有限公司
桃園市桃園區中正路1353號15樓

附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm(μ g/g)

| 測試項目 | CAS NO. | LOD | 測試項目 | CAS NO. | LOD |
|-------------------------|-------------|------|---------------------------------------------|-------------|------|
| Simvastatin | 79902-63-9 | 600 | Tetracycline | 60-54-8 | 750 |
| Spironolactone | 52-01-7 | 300 | Tetramethylpyrazine | 1124-11-4 | 2400 |
| Stanozolol | 10418-03-8 | 2100 | Theobromine | 83-67-0 | 600 |
| Strychnine | 57-24-9 | 900 | Theophylline | 58-55-9 | 600 |
| Sulfadiazine | 68-35-9 | 600 | Thiodimethylsildenafil | 856190-47-1 | 450 |
| Sulfadimethoxine | 122-11-2 | 750 | Thiohomosildenafil | 479073-80-8 | 450 |
| Sulfamerazine | 127-79-7 | 450 | Thioridazine | 50-52-2 | 300 |
| Sulfamethazine | 57-68-1 | 600 | Thiosildenafil | 479073-79-5 | 450 |
| Sulfamethizole | 144-82-1 | 600 | Tiletamine | 14176-49-9 | 300 |
| Sulfamethoxazole | 723-46-6 | 600 | Timolol Maleate | 26921-17-5 | 150 |
| Sulfamethoxypyridazine | 80-35-3 | 450 | Tinidazole | 19387-91-8 | 900 |
| Sulfamonomethoxine | 1220-83-3 | 4650 | Tolbutamide | 64-77-7 | 375 |
| Sulfanilamide | 63-74-1 | 375 | Topiramate | 97240-79-4 | 450 |
| Sulfapyridine | 144-83-2 | 2400 | Trazodone hydrochloride | 19794-93-5 | 3000 |
| Sulfaquinoxaline | 59-40-5 | 4740 | Triamcinolone | 124-94-7 | 900 |
| Sulfathiazole | 72-14-0 | 600 | Triamcinolone acetonide | 76-25-5 | 4800 |
| Sulfinpyrazone | 57-96-5 | 750 | Triazolam | 28911-01-5 | 150 |
| Sulfisomidine | 515-64-0 | 3000 | Trimethoprim | 738-70-5 | 1500 |
| Sulfisoxazole | 127-69-5 | 450 | Tripolidine | 486-12-4 | 60 |
| Sulindac | 38194-50-2 | 750 | Uscnic acid | 125-46-2 | 3600 |
| Sulpiride | 15676-16-1 | 1140 | Vardenafil | 224785-90-4 | 1800 |
| Synephrine | 94-07-5 | 450 | Vardenafil analogue(Molecular weight312.37) | 224789-21-3 | 1800 |
| Tadalafil | 171596-29-5 | 600 | Verapamil | 152-11-4 | 60 |
| Terbinafine | 91161-71-6 | 300 | Xanthinol Niacinate | 437-74-1 | 1050 |
| Terfenadine | 50679-08-8 | 450 | Yohimbine | 146-48-5 | 1500 |
| Testosterone | 58-22-0 | 600 | Zolazepam HCl | 31352-82-6 | 60 |
| Testosterone propionate | 57-85-2 | 3000 | Zolpidem | 82626-48-0 | 300 |
| Tetracaine | 94-24-6 | 600 | -- | -- | -- |

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號： PUG22400882

日期： 2022年05月09日

頁數： 9 of 9



生麗國際股份有限公司
桃園市桃園區中正路1353號15樓

樣品照片

PUG22400882



PUG22400882



This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained herein reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.